Yajian Jiang

ORCID: 0000-0003-1183-9875
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Histone Deacetylase Inhibitors Research
  • Advanced biosensing and bioanalysis techniques
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Selenium in Biological Systems
  • Epigenetics and DNA Methylation
  • Metabolism, Diabetes, and Cancer
  • Cancer, Hypoxia, and Metabolism
  • Genomics and Chromatin Dynamics
  • Cancer Treatment and Pharmacology
  • Single-cell and spatial transcriptomics
  • DNA Repair Mechanisms
  • Sirtuins and Resveratrol in Medicine
  • Mesenchymal stem cell research
  • RNA Interference and Gene Delivery
  • Protein Degradation and Inhibitors
  • Trace Elements in Health
  • Lung Cancer Research Studies
  • Glioma Diagnosis and Treatment
  • Nuts composition and effects
  • Microtubule and mitosis dynamics
  • Biochemical and Molecular Research
  • Glutathione Transferases and Polymorphisms
  • Monoclonal and Polyclonal Antibodies Research

AbbVie (United States)
2024

Baylor College of Medicine
2016-2022

Southern Medical University
2019

First Affiliated Hospital Zhejiang University
2013

Nuclear NAD + homeostasis governed by NMNAT1 prevents apoptosis in AML stem cells suppressing p53.

10.1126/sciadv.abf3895 article EN cc-by-nc Science Advances 2021-07-21

7037 Background: Gemcitabine + oxaliplatin (GemOx) is commonly used with rituximab to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL); however, outcomes are suboptimal: 33% complete response (CR) rate; 5 mo median progression-free survival (PFS); 10 overall (OS; Cazelles et al, Leuk Lymphoma 2021). We report additional efficacy and safety results of epcoritamab GemOx in difficult-to-treat R/R DLBCL (EPCORE™ NHL-2 phase 1/2 trial, NCT04663347). Methods: Adults CD20...

10.1200/jco.2024.42.16_suppl.7037 article EN Journal of Clinical Oncology 2024-06-01

Background: Based on 10 years’ research, we have established MagIC-TT (Magnetism-induced cell target transplantation) platform to enhance transplantation of therapeutic cells, such as hematopoietic stem (HSC) and mesenchymal bone marrow (Blood 2010 116: 2625; 2014 124: 2416; 2015 126:5404 & 5409; 2017 130: 4952 5447). To increase the HSC homing, many researches intra-bone intra-artery been carried out, but effect is limited (According our most HSCs were flushed peripheral circulation in...

10.1097/01.hs9.0000564520.06999.9c article EN cc-by-nc-nd HemaSphere 2019-06-01
Coming Soon ...